Moleculin Biotech Files 8-K Current Report
Ticker: MBRX · Form: 8-K · Filed: Aug 1, 2025 · CIK: 1659617
Sentiment: neutral
Topics: current-report, sec-filing
TL;DR
Moleculin Biotech just dropped an 8-K, check it for updates.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on August 1, 2025, reporting an event that occurred on the same date. The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company is incorporated in Delaware and its principal executive offices are located in Houston, Texas.
Why It Matters
This 8-K filing indicates a significant event or update from Moleculin Biotech, Inc. that requires immediate disclosure to the public and investors.
Risk Assessment
Risk Level: low — This filing is a standard 8-K current report and does not inherently contain negative financial or operational news.
Key Numbers
- 001-37758 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-4671997 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- August 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Houston, TX (location) — Address of principal executive offices
FAQ
What specific event triggered this 8-K filing?
The filing does not specify the exact event, only that it is a current report filed on August 1, 2025.
What is the primary business of Moleculin Biotech, Inc.?
Moleculin Biotech, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where are Moleculin Biotech's principal executive offices located?
Their principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
What is the filing date of this 8-K report?
The filing date, and the date of the earliest event reported, is August 1, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 1, 2025 regarding Moleculin Biotech, Inc. (MBRX).